CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
galiximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00516217
NCT00516217Phase 2Completed
CompareCT.gov

A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma

Alliance for Clinical Trials in Oncology·interventional·Posted Aug 15, 2007·Updated Jul 6, 2016

In Brief

A Phase 2 clinical trial evaluating galiximab for Lymphoma. Completed, enrolled 30 participants across 56 sites.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying how well galiximab works in treating patients with relapsed or refractory Hodgkin's lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2007
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2011
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.9 years ago

Interventions

galiximabbiological